Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 3/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12039805 | 0.92 | OPRK1 (0.53) | BCHEOPRK1OPRM1OPRD1AOC3 | |
| SCHEMBL13995266 | 0.92 | OPRK1 (0.53) | BCHEOPRK1OPRM1OPRD1AOC3 | |
| SCHEMBL9511821 | 0.88 | BCHE (0.51) | BCHEOPRK1AOC3SLC6A2SLC6A4 | |
| SCHEMBL14006363 | 0.88 | BCHE (0.51) | BCHEOPRK1AOC3SLC6A2SLC6A4 | |
| SCHEMBL20803803 | 0.87 | BCHE (0.52) | BCHEOPRK1OPRM1OPRD1AOC3 | |
| SCHEMBL10147148 | 0.87 | CALM1 (0.53) | BCHEOPRK1AOC3SLC6A2SLC6A4 | |
| SCHEMBL12126089 | 0.87 | MAOB (0.50) | BCHEOPRK1OPRM1OPRD1SLC6A2 | |
| SCHEMBL12059219 | 0.85 | HRH3 (0.53) | BCHEOPRK1OPRM1OPRD1AOC3 | |
| SCHEMBL21675626 | 0.84 | OPRK1 (0.47) | BCHEOPRK1OPRM1OPRD1AOC3 | |
| SCHEMBL800998 | 0.82 | POLB (0.54) | BCHEOPRK1OPRM1AOC3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355708-A1 | POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS, INC. | 2017-12-14 | — | — | US | disclosed |
| US-20140349992-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2014-11-27 | — | — | US | disclosed |
| US-8772301-B2 | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof | SUNOVION PHARMACEUTICALS, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | GRM5, GRM2, GRM1 | BCHE 483/4885OPRK1 113/4885OPRM1 156/4885 |
| US-20170355708-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | BCHE 4077/4885OPRK1 334/4885OPRM1 1377/4885 |
| US-20140349992-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | GRM5, GRM2, GRM1 | BCHE 483/4885OPRK1 113/4885OPRM1 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.